Cometriq is owned by Exelixis.
Cometriq contains Cabozantinib S-Malate.
Cometriq has a total of 7 drug patents out of which 0 drug patents have expired.
Cometriq was authorised for market use on 29 November, 2012.
Cometriq is available in capsule;oral dosage forms.
Cometriq can be used as method of treating medullary thyroid cancer.
The generics of Cometriq are possible to be released after 10 February, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7579473 | EXELIXIS | c-Met modulators and methods of use |
Aug, 2026
(3 years from now) | |
US11091439 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US8877776 | EXELIXIS | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11098015 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US11091440 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(6 years from now) | |
US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(8 years from now) | |
US11298349 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(8 years from now) |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 29 November, 2012
Treatment: Method of treating medullary thyroid cancer
Dosage: CAPSULE;ORAL
47
United States
21
Japan
15
Australia
12
European Union
11
Korea, Republic of
8
Spain
8
Taiwan
6
Hong Kong
6
Denmark
6
New Zealand
5
Poland
5
Canada
5
Croatia
5
Slovenia
4
China
4
EA
4
Portugal
3
Austria
3
Cyprus
3
Israel
3
Mexico
2
Brazil
2
Argentina
2
South Africa
2
Hungary
1
RS
1
Singapore
1
San Marino
1
Georgia
1
Netherlands
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic